Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

Drug Metabolism and Disposition

Volumn 20, Issue 5, 1992, Pages 706-713

  Grochow, L B ^a   Rowinsky, E K ^a   Johnson, R ^a   Ludeman, S ^a   Kaufmann, S H ^a   McCabe, F L ^a   Smith, B R ^a   Hurowitz, L ^a   DeLisa, A ^a   Donehower, R C ^a   Noe, D A ^a  

^a Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; HYDROXYACID; LACTONE; NSC 609669; SKF 105992; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; LEUKEMIA; MOUSE; NEUTROPENIA; NONHUMAN; PH; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MICE; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOPOTECAN;

EID: 0026646768     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)